pyruvate carboxylase Inhibitors
2 drugsAbout pyruvate carboxylase
Pyruvate carboxylase is a biotin-dependent enzyme crucial for gluconeogenesis and lipogenesis. It catalyzes the ATP-dependent carboxylation of pyruvate to oxaloacetate, replenishing the tricarboxylic acid cycle and providing precursors for glucose and lipid synthesis.
Pyruvate carboxylase is a potential therapeutic target due to its involvement in fundamental metabolic pathways. Currently, there is no genetic evidence directly linking pyruvate carboxylase to specific diseases.
Two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, target pyruvate carboxylase. Both drugs are marketed by AM REGENT for unspecified indications.
Top pyruvate carboxylase Drugs
AM REGENT is the only company with approved drugs targeting pyruvate carboxylase.
Low competition presents an opportunity, but also indicates potential market risk or high entry barriers.
pyruvate carboxylase Drug Modality Landscape
Modalities
Routes of Administration
pyruvate carboxylase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like biologics to differentiate from existing small molecule drugs.
pyruvate carboxylase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on pyruvate carboxylase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
pyruvate carboxylase Drug Approval Timeline (2020 - 2020)
The first and most recent drugs, MULTRYS and TRALEMENT, were both approved in 2020.
Recent approvals suggest renewed interest, but limited timeline data indicates uncertain market trajectory.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on pyruvate carboxylase. A trial counts if an approved drug acting on pyruvate carboxylase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.